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Abstract
Development of a novel and effective vaccine against Mycobacterium tuberculosis (M.tb) is a challenging for preventing TB
infection. In this study, a novel nanoparticle-based recombinant DNA vaccine was developed, which contains Esat-6 three T
cell epitopes (Esat-6/3e) and fms-like tyrosine kinase 3 ligand (FL) genes (termed Esat-6/3e-FL), and was enveloped with
chitosan (CS) nanoparticles (nano-chitosan). The immunologic and protective efficacy of the nano-chitosan-based DNA
vaccine (termed nano-Esat-6/3e-FL) was assessed in C57BL/6 mice after intramuscular prime vaccination with the plasmids
DNA and nasal boost with the Esat-6/3e peptides. The results showed that the immunized mice remarkably elicited
enhanced T cell responses and protection against M.tb H37Rv challenge. These findings indicate that the nano-chitosan can
significantly elevate the immunologic and protective effects of the DNA vaccine, and the nano-Esat-6/3e-FL is a useful
vaccine for preventing M.tb infection in mice.
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Introduction
Tuberculosis (TB) infected by Mycobacterium tuberculosis (M.tb) has
plagued humankind worldwide for many years [1]. Although
bacillus Calmette-Guerin (BCG) is an effective vaccine for
childhood TB, it produces incomplete and variable protection in
adult TB [2]. Furthermore, BCG is also an attenuated vaccine that
cannot be safely given to the persons infected with human
immunodeficiency virus (HIV). Thus, a new and efficient vaccine
against TB is urgently required.
Control of M.tb infection greatly depends on T cell-mediated
immune responses [3]. The 6 kDa early secretory antigenic target
(Esat-6), which presents in virulent mycobacterial strains and
absents in BCG [4], is critical for M.tb immunogenicity and
virulence. Because Esat-6 protein can be recognized by T cells and
B cells [5], and it has attracted intense interests in vaccine
development. Given that M.tb Esat-6 gene is located in virulent
M.tb [6], avoiding Esat-6 adverse reaction in the vaccine studies is
also indeed important.
It has been reported that the DNA vaccines based on T cell
epitopes of M.tb antigens can induce efficient immune responses,
and decrease side effects and increase safety and stability of
vaccines [7,8]. However, DNA poor delivery to antigen presenting
cells (APCs) and the rapid inactivation mediated by DNase results
in low immunogenicity of DNA vaccines [9]. Thus, elevating DNA
vaccine delivery efficiency of DNA vaccine and protecting DNA
from degradation are important for enhance DNA vaccine
potency.
Several documents have reported that fms-like tyrosine kinase 3
ligand (FL) plays an important role in proliferation and
differentiation of myeloid and lymphoid progenitor cells as well
as dendritic cells (DCs) [10]. Moreover, FL has a strong adjuvant
effects that augment DC recruitment and expansion, as well as
increase antigen uptake and cross presentation [11,12].
Chitosan (CS) is a non-toxic biodegradable and biocompatible
polycationic polymer, which can not only bind DNA and protect it
from nuclease degradation [13,14,15,16], but also exhibit potential
adjuvant properties, such as promoting endocytotic uptake and
elevating immune responses. Additionally, chitosan nanoparticles
(nano-chitosan) possess lower cytotoxicity and more stability
[17,18,19,20,21].
In order to evaluate the immunologic and protective efficacy of
CS nanoparticle-based DNA vaccine expressing T cell epitopes of
Esat-6 and FL against M.tb infection, in the present study, the
three T cell epitopes of Esat-6 (Esat-6/3e) were predicted and
selected based on the pitope prediction software analyses. Then, a
recombinant plasmid DNA vaccine that contains the genes of
Esat-6 three T cell epitopes (Esat-6/3e) was constructed and
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identified. Subsequently, the recombinants were enveloped with
nano-chitosan, and the nano-chitosan-based recombinants were
identified, and validated the expression in rat glomerular
mesangial cells (GMCs). More importantly, the immunologic
and protective effects against M.tb infection mediated by the nano-
chitosan-based DNA vaccines were evaluated in vivo in mouse
models.
Results
Prediction of T cell epitopes and identification of
recombinant Esat-6/3e-FL plasmid
Based on MHC-binding scores of the MHCpre software
analyses (http://www.syfpeithi.com/scripts/MHCSr.dll/home.
htm; http://tools.immuneepitope.org) and literatures [22], the
three T cell epitopes of Esat-6 were selected for the DNA vaccine
development as follow: Esat-64–18 (QQWNFAGIEAAASAI), Esat-
622–36 (VTSIHSLLDEGKQSL) and Esat-656–70 (QKWDATA-
TELNNALQ). To protect the epitopes against amalgamation and
enhance efficacy of intracellular protease incising [23], the Ala-
Ala-Tyr (AAY) linker and a his tag were inserted into pIRES
(vector) and pIRES-FL plasmids, named pIRES-Esat-6/3e (Esat-
6/3e) and pIRES-Esat-6/3e-FL (Esat-6/3e-FL), respectively
(Figure 1A.). To verify whether the recombinant plasmids can
express the corresponding protein, the plasmids were transfected
into rat GMCs for 60 h, and the expression of his tag and FL
protein was determined by Western blot (Figure 1B).
Diameter, zeta potential and shape of nano-chitosan and
nano-Esat-6/3e-FL plasmids
The diameter and dispersing degree of nano-chitosan particles
were 311.2634 nm and 0.35 respectively. Their zeta potential was
30.6 mV. After the recombinant Esat-6/3e-FL plasmids were
coated with nano-chitosan (nano-Esat-6/3e-FL), the diameter and
zeta potential of the nano-plasmids were 314.8638 nm and
33.6 mVseparately, and their dispersing degree was 0.39 (Figure
S1A, and S1B). Moreover, the particles of nano-chitosan and
nano-Esat-6/3e-FL displayed an irregular solid sphere, and their
diameters were from 280 to 330 nm (Figure 1C).
Stability, transfection efficacy and expression of nano-
Esat-6/3e-FL plasmid
The nano-Esat-6/3e-FL plasmids were first digested by different
concentrations of DNase I. When agarose gel electrophoresis was
performed, the Esat-6/3e-FL plasmid DNAs departed from the
sample well, but the corresponding nano-plasmids stayed in the
well (Figure S2A). The different volume ratio of nano-chitosan and
Esat-6/3e-FL mixture was digested by the same dose of DNase I.
The results manifested that Esat-6/3e-FL plasmids were well
digested when the ratio was at 1:4 (Figure S2B). In addition, the
transfection efficiency and cytopathic effect of pGCsi-GFP
enveloped by nano-chitosan (nano-chitosan-GFP) or liposome-
2000 were observed in rat GMCs. The results confirmed that the
CPE of GMCs transfected with nano-chitosan-GFP at 48 h or
72 h was markedly lower than that of GMCs transfected with
pGCsi-GFP coaded by liposomes-2000 (Figure S3). Moreover, the
nano-Esat-6/3e-FL plasmids could also express the corresponding
proteins (Figure 1D).
Production of cytokines and expression of T-bet, Gata-3
from the splenocytes of the nano-Esat-6/3e-FL-
immunized mice
In order to evaluate T cell immune responses elicited by the
nano-Esat-6/3e-FL vaccination, splenocytes from the immunized
mice were collected and cultured. The amounts of IFN-c, IL-12,
IL-4 and IL-10 in the supernatant were detected by ELISA. The
levels of IFN-c and IL-12 in the mice vaccinated with nano-Esat-
6/3e-FL or nano-Esat-6-FL were obviously higher than those with
other plasmids, which even exceed the levels in BCG treatment
group.Furthermore, mice immunized with nano-Esat-6/3e-FL
elicited much higher levels of IFN-c and IL-12 than those
immunized with Esat-6/3e-FL. However, the levels of IL-4 and
IL-10 from the mice vaccinated with BCG were the highest among
all the vaccinated mice (Figure 2A). In addition, the expression
levels of T-bet mRNA and protein in nano-Esat-6/3e-FLimmu-
nized mice were obviously higher than those in the other groups
treated with other plasmids or BCG (Figure 2B). However, Gata-3
mRNA and protein expressions did not show obvious changes
among all the groups. These results suggested that the mice
immunized with nano-Esat-6/3e-FL and nano-Esat-6-FL could
induce a stronger Th1-polarized response.
Proliferation of spleen cells and numbers of IFN-c+ T cells
from the nano-Esat-6/3e-FL immunized mice
To verify the efficacy of immunologic reaction induced by
nano-Esat-6/3e-FL vaccination, proliferation of spleen cells from
the immunized mice was detected. As shown in Figure 3A, the SI
increased more conspicuously in the mice with nano-Esat-6/3e-FL
vaccination than that in other groups. The SIs of the mice treated
with nano-Esat-6-FL and BCG were also significantly elevated,
but no marked difference, compared with the nano-Esat-6/3e-FL
immunization group.
To further determine whether the nano-Esat-6/3e-FL can
trigger high T cell responses, IFN-c –producing T cells of
immunized mice were evaluated using ELISPOT assays. IFN-c+ T
cell numbers (spot forming cell, SFC) in the mice with nano-Esat-
6/3e-FL vaccination were much higher than those in the mice
immunized with Esat-6/3e-FL. Although IFN-c+ T cell numbers
in the mice immunized with nano-Esat-6-FL were the highest,
there was no significant difference in comparison to the mice
immunized with nano-Esat-6/3e-FL vaccine (Figure 3B).
CTL activity of mice triggered by nano-Esat-6/3e-FL
immunization
To assess the cytolytic capability of CTLs induced by nano-
Esat-6/3e-FL vaccination, an in vivo cytotoxicity assay was
performed. As shown in Figure 4, a significantly increased lyses
were founded in the mice immunized with nano-Esat-6/3e, Esat-
6/3e-FL, nano-Esat-6 or nano-Esat-6-FL separately (Figure 4). In
addition, much higher cytolytic activity was observed in the mice
immunized with nano-Esat-6/3e-FL or nano-Esat-6-FL, though
there was no significant difference between these different groups,
which also overtopped markedly BCG vaccination.
Protective effects against M.tb H37Rv challenge from the
mice immunized with nano-Esat-6/3e-FL
To determine the protective potential of nano-Esat-6/3e-FL
vaccination, one week after the last boost with Esat-6/3e peptides,
the vaccinated mice were intratracheally challenged with 16106
bacilli M.tb H37Rv. The bacterial burdens in the lungs and
spleens, including pulmonary injury were observed at 4 weeks post
challenge. As shown in Figure 5, the reduction of M.tb colonies was
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significantly observed both in the lungs (Figure 5A) and spleens
(Figure 5B) in the mice with nano-Esat-6/3e-FL immunization,
and the value of log10 CFU was 0.40360.023 and 0.32460.062,
respectively, although the log10 CFU value in the mice vaccinated
with nano-Esat-6/3e-FL plasmids was similar to that of the mice
treated with nano-Esat-6-FL plasmids. Meanwhile, the burden of
log10 CFU in the lungs from these two groups was sharply
decreased compared with that from BCG vaccination. These
findings indicated that immune responses of the mice induced by
nano-Esat-6/3e-FL (including nano-Esat-6-FL) plasmid DNA
vaccine could indeed lead to an enhanced defense.
On the other hand, the lung tissues of the mice vaccinated with
nano-chitosan, nano-pIRES and nano-FL showed widespread and
severe interstitial pneumonia including larger diffuse granuloma
and infiltration of inflammatory cells after M.tb H37Rv infection,
while the mice immunized with nano-Esat-6/3e-FL (including
nano-Esat-6-FL or BCG) displayed moderate damage with
relatively fewer cell infiltration, smaller granulomas and better
lung structure (Figure 5C).
Additionally, to determine whether the mice immunized with
nano-Esat-6/3e-FL affect the influx of T cells and macrophages,
the lung sections were stained with anti-CD3 or anti-F4/80
antibody. The results displayed that the numbers of CD3 (Figure
S4A) and F4/80 (Figure S4B) positive cells in the mice immunized
with nano-Esat-6/3e-FL were much more than the mice from
other treatment groups. Furthermore, the mice treated with nano-
Esat-6/3e-FL possessed more intact alveolar tissue, implicating the
inflammatory changes mediated by M.tb were attenuated (Figure
S4C). These results suggest that the nano-chitosan-based DNA
vaccine could induce a strong and effective protection against M.tb
challenge in the immunized mice.
Discussion
Previous studies have reported that one of major contributors to
the virulence and intercellular spread of M.tb is Esat-6 secretion
system 1 (ESX-1) that is lost in BCG [24,25,26,27,28]. In addition,
Esat-6 also contains a large number of antigen epitopes recognized
by T and B cells. Immunization with Esat-6 in mice not only
induces highlevels of IFN-c and low bacterial loads after M.tb
challenge [29,30,31,32,33,34]. Since epitope vaccines can over-
come safety problem and induce potent immune responses [35–
37], in our previous [38] and present studies, three T cell epitopes
of Esat-6 (Esat-64–18, Esat-622–36 and Esat-656–70), which contain
Th1 and/or CTL epitopes [39–42], were selected according to
higher scores via prediction software analyses.
In view of relatively low immunogenicity of DNA vaccine [13],
the strategy of increasing delivery efficiency and protecting DNA
Figure 1. Construction and identification of pIRES-Esat-6/3e-FL (namely Esat-6/3e-FL). A. Schematic representation of Esat-6/3e-FL. B. The
expression of his tag and FL proteins from Esat-6/3e or Esat-6/3e-FL plasmids was determined using Western blot after transfection of the plasmids
into rat GMCs for 60 h (1: pIRES-Esat-6/3e. 2: pIRES-Esat-6/3e-FL. 3: pIRES-FL. 4: pIRES). C. The irregular solid spheres of nano-chitosan and nano-Esat-
6/3e-FL plasmids under EM. D. The expression of his or FL proteins from the Esat-6/3e-FL plasmids enclosed with chitosan nanoparticle (nano-Esat-6/
3e-FL) was confirmed using Western blot with anti-his or anti-FL antibody at 60 h after transfection into rat GMCs (1: MEM. 2: nano-pIRES. 3: nano-
Esat-6/3e-FL).
doi:10.1371/journal.pone.0061135.g001
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from degradation may elevate the protective effects. FL is used as
an effective adjuvant due to its enhancing antigen presentation
[21]. Furthermore, in our previous experiments [38], co-delivery
of FL for ESAT-6 epitopes DNA vaccines was confirmed to
remarkably increase the efficacy of immunity and protection in
mice.
It has been known that chitosan (CS) can effectively bind to
DNA and protect it from nuclease degradation, and DNA
packaged with nano-chitosan can improve cell uptake and vaccine
delivery [13,14,15,16,41,43,44,45,46,47]. In the present study, the
recombinant candidate plasmid that contained 3 T cell epitopes
and FL (pIRES-Esat-6/3e-FL), as well as the recombinant control
plasmids i.e. pIRES-Esat-6/3e, pIRES-Esat-6 (containing full
length of ESAT-6) and pIRES-FL (only containing FL) were first
constructed and then enclosed with nano-chitosan. Our results
showed that the nano-chitosan-based plasmids could transfect into
GMCs and the corresponding protein was effectively expressed.
Although the mice immunized with the control plasmids and BCG
obviously elevated T cell responses and CTL activities, much more
responses and effects were observed in the mice vaccinated with
nano-Esat-6/3e-FL. Moreover, those immunized mice displayed
remarkably protective efficacy, including the inhibition of M.tb
growth and lung damage, but the better effects were seen in the
mice immunized with nano-Esat-6/3e-FL and nano-Esat-6-FL,
implicating that FL and nano-chitosan generated a markedly
synergistic role as immune adjuvant for the DNA vaccine. Since
lower cytotoxicity of nano-Esat-6/3e plasmid was demonstrated in
rat GMCs, thus we think that the nano-Esat-6/3e plasmid DNA
might be a better vaccine.
On the other hand, the mice vaccinated with BCG could not
only induce high levels of IFN-c and IL-12, increased T-bet
expression and IFN-c+ T cells and augmented CTL activity, but
also provide strong protection. However, the immune response
efficiency of the mice with BCG immunization were relatively
lower than that of the mice with nano-Esat-6/3e-FL (including
nano-Esat-6-FL) vaccination, indicating that the nano-Esat-6/3e-
FL DNA vaccine can mediate more powerful T cell responses and
may be superior to BCG. Furthermore, since the pathological
changes of mice vaccinated with nano-Esat-6/3e-FL were
markedly lower than those of the mice treated with nano-whole
Esat-6 and FL (nano-Esat-6-FL), we consider that the plasmid
DNA vaccine encapsulated with nano-chitosan (nano-Esat-6/3e-
FL) is relatively better than nano-Esat-6-FL plasmid DNA.
Reportedly, Bennekov’ study [48] showed that the adenoviral
construct induced a strong CD8 response predominantly targeted
to the epitope Esat-615–29, but there was no significant protection
against M.tb infection. Thus, in our current experiment, we
selected the three epitopes (Esat-64–18, Esat-622–36 and Esat-656–70)
that based on the computer prediction. Our results demonstrated
that the mice immunized with nano-Esat-6/3e-FL plasmid DNA
vaccine not only elicited enhanced T cell responses, but also
remarkably elevated the protection against M.tb challenge.
Figure 2. Splenocytes of the mice immunized with different plasmids were cultured and stimulated with Esat-6/3e (10 mg/ml) for
72 h, and the production of IFN-c, IL-12, IL-4 and IL-10 in the splenocyte supernatants and expression of T-bet and Gata-3 in the
splenocytes were measured by ELISA and Western blot, respectively. A. The levels of Th1 type cytokines (IFN-c and IL-12) and Th2 type
cytokines (IL-4 and IL-10). B. The expression levels of T-bet or Gata-3 mRNA and protein. The representative graph and histograms in the immunized
mice were showed. The experiments were performed in three times. All data are from one representative of three experiments, and presented as the
mean value 6 SD (n = 6). The statistics were performed with one-way ANOVA. NS: P.0.05; *P,0.05 and ***P,0.001 versus the mice with nano-
chitosan, nano-pIRES and nano-FL immunization respectively. The other significant differences among the mice vaccinated with nano-Esat-6/3e-FL,
nano-Esat-6/3e, Esat-6/3e-FL, nano-Esat-6, nano-Esat-6-FL and BCG were displayed on the figure directly.
doi:10.1371/journal.pone.0061135.g002
Figure 3. The proliferation of the splenocytes and number of IFN-c+ T cells of the mice immunized by nano-Esat-6/3e-FL. A.
Splenocytes were cultured and stimulated with the Esat-6/3e (10 mg/ml) for 72 h. The stimulation index (SI) of splenocytes in the mice treated with
different vaccines was calculated to determine the proliferation activity. B. The numbers of IFN-c+ T cells from the splenocytes were quantified by
ELISPOT assays. Data are one representative of three experiments and presented as mean value 6 SD (n = 6). The statistics were performed with one-
way ANOVA. NS: P.0.05; ***P,0.001 versus the mice treated with nano-chitosan, nano-pIRES and nano-FL plasmids. The differences among other
treatments were shown directly on the figure.
doi:10.1371/journal.pone.0061135.g003
Nano-Chitosan-Based Vaccine Encoding Esat-6
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61135
Figure 4. The CTL activity of the mice elicited by nano-Esat-6/3e-FL or other plasmids. Splenocytes from naive mice pulsed with
(CFSEhigh) or without (CFSElow) peptides were transferred into the immunized mice. The representative histograms (A) and percentages (B) of
specific lysis in the immunized mice were compared. Data are one representative results from three performed experiments, and presented as the
mean 6 SD (n= 6). NS: P.0.05; *P,0.05; ***P,0.001 versus the mice treated with nano-chitosan, nano-pIRES or nano-FL plasmids; the other
differences among nano-Esat-6/3e-FL, nano-Esat-6/3e, Esat-6/3e-FL, nano-Esat-6, nano-Esat-6-FL and BCG treatments were showed on the figure
directly.
doi:10.1371/journal.pone.0061135.g004
Figure 5. The protection efficacy against M.tb infection of the mice immunized with different vaccines. Mice vaccinated with different
plasmids and boosted with Esat-6/3e peptides for two times were infected with 16106 bacilli of M.tb H37Rv for 4 weeks. Bacterial loads in the lungs
(A) and spleens (B) of these mice were examined and the sections of the lung tissues from these mice were performed HE staining. Representative
histologic changes (1006) depicted the lung tissue of the infected mice (C).
doi:10.1371/journal.pone.0061135.g005
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Additionally, it is worth mentioning that in vitre experiment, the
splenocytes had also been stimulated with PPD, but the data (not
shown) were similar to data of the splenocytes with Esat-6/3e
peptides. Ergo, to demonstrate the increased antigen-specific
immune responses, we used the data from the epitope peptides
stimulation in the paper. In terms of such amount of IL-10 and IL-
4 (look higher) in nano-chitosan, nano-pIRES and nano-FL (see
Fig. 2), here we explain that IL-10 and IL-4 have a basic level in
mice, while the relatively lower levels of IL-10 and IL-4 in the mice
treated with the plasmid vaccines might be related with elevated
Th1 and decreased Th2 responses. However, the mechanisms
need to be explored in the future.
In summary, our data demonstrated that the selected three T
cell epitopes of Esat-6 were dominant epitopes for Th1 cells and
CTLs which can significantly increase Th1 polarization reactions
and CTL activity. Moreover, FL is a critical immunostimulatory
adjuvant that promoted more strong immune responses and
protection against M.tb induced by DNA vaccines. More
importantly, nano-chitosan could also significantly enhance the
vaccination effects of Esat-6/3e-FL DNA vaccine, such as strong
Th1 and CTL immune responses and inhibition of M.tb growth.
Collectively, our findings indicate that the nano-chitosan-based
DNA vaccine (nano-Esat-6/3e-FL) is a novel and useful tool for
preventing M.tb infection.
Materials and Methods
Animals
Eight-week-old female C57BL/6 mice (H-2b) were purchased
from the central animal laboratory of Yangzhou University
(China), and maintained under specific pathogen-free conditions
(eight in each group). All the experiments were conducted
according to the Institutional Ethical Guidelines for Animal
Experiments of Nanjing Medical University (permit number:
2010257).
T cell epitope prediction, plasmid construction and
identification
The plasmids of pIRES-Esat-6-FL (containing full length of
Esat-6 and FL) and pIRES-Esat-6 (only containing full length of
Esat-6) as well as pIRES-FL (only containing full length of FL)
have been previously described [7] and kept in our lab. The
primary structure of Esat-6 antigen was analyzed by epitope
prediction software online (http://www.syfpeithi.com/scripts/
MHCSr.dll/home.htm; http://tools.immuneepitope.org). Three
T cell epitopes, namely Esat-64–18 (QQWNFAGIEAAASAI), Esat-
622–36 (VTSIHSLLDEGKQSL) and Esat-656–70 (QKWDATA-
TELNNALQ) were sorted based on their scores [38]. A his tag,
the three peptides and Ala-Ala-Tyr (AAY) linker were synthesized
and inserted into pIRES or pIRES-FL plasmids, which were
termed pIRES-Esat-6/3e (Esat-6/3e) and pIRES-Esat-6/3e-FL
(Esat-6/3e-FL). Thereafter, these plasmids were prepared and
purified with endoFree plasmid maxi kit (Qiagen, Germany) and
transfected into rat GMCs. Subsequently, the expression of his and
FL protein of these plasmids was detected using Western blot [38].
Chitosan nanoparticle, nano-plasmid DNA preparation
and identification
Chitosan (CS) was purchased from Treechem. Ltd (Shanghai,
China), and dissolved in 1% acetic acid and mixed with 0.1%
pentasodium triphosphate (TPP), then the formation of chitosan-
TPP nanoparticles started spontaneously via the TPP initiated
ionic crosslink and coacervation [21]. To get mixture of nano-
chitosan and plasmid DNA, both prepared nano-chitosan and
plasmid DNA suspension heated and mixed in different volume.
Thereafter, the particle size, zeta potential and polydispersity of
nano-chitosan and nano-Esat-6/3e-FL plasmids were measured by
a Malvern Zetasizer 3000-HS at 633 nm. The morphological
shape of the nanoparticles was observed by electron microscopy
(EM).
The suspensions of nano-chitosan and nano-plasmid DNA were
separated by ultra centrifugation. The amount of free-DNA in the
supernatant was detected at 595 nm, and the DNA encapsulation
efficiency (EE) was calculated using Eq: EE = (total amount DNA–
free amount DNA in supernatant)/total amount DNA6100%.
Meantime, different gradient amount of DNase I (0.02U, 0.04U
and 0.1U) was added into the naked plasmid DNA and nano-
plasmid DNA with the same quantity for 15 min. The mixture was
electrophoresed with 2% agar. Furthermore, these plasmids were
transfected into glomerular mesangial cells (GMCs) separately and
cultured for 60 h. Thereafter, the lysate of GMCs was electro-
phoresed on SDS-PAGE gels, and stained with anti-his or anti-FL
mAb (Santa Cruz, USA).
Esat-6 peptide, BCG and M.tb H37Rv preparation
The Esat-6 peptides (Esat-6/3e) comprising the 3 T cell epitopes
were synthesized by Sangon Biotech Co. Ltd (Shanghai, China),
and confirmed to be of .90% purity by high-performance liquid
chromatography and mass spectrometry profiles. BCG (Denmark
strain 1331) was provided by Center for Disease Control of Jiangsu
Province in China. A virulent M.tb H37Rv strain (ATCC 27294)
supplied by National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China) was grown in 7H9 liquid
medium supplemented with albumin-dextrose-catalase enrich-
ment.
Vaccine immunization and M.tb H37Rv challenge
All female C57BL/6 mice housed in specific pathogen free
conditions, and were randomly assigned to 9 groups (eight in each
group) as shown in Table 1. To compare the different effects on T
cell immune response in the mice immunized various relative
materials, the mice of candidate group were treated with nano-
Esat-6/3e-FL plasmid DNA. And the mice of control groups
treated with nano-Esat-6/3e, nano-Esat-6-FL, nano-Esat-6, nano-
FL, nano-chitosan, nano-pIRES, Esat-6/3e-FL and BCG, respec-
tively. In nano-plasmids treatment, the mice were injected
intramuscularly three times at 3-week intervals in both quadriceps
muscles with 100 ml nano-chitosan or 100 ml different nano-
plasmids (containing 100 mg DNA, separately). In Esat-6/3e-FL
treatment, the mice were vaccinated with 100 ml Esat-6/3e-FL
plasmids (containing 100 mg DNA) without nano-chitosan envel-
opment. In BCG treatment, the mice were injected subcutane-
ously with 106 BCG only once at equal pace. Three weeks after
two immunizations, the mice were dripped via airway with 25 mg
Esat-6/3e peptides two times at 1-week interval. In order to induce
higher immune responses, the animals were boosted [49], and 2
weeks after the last peptides boost, parts of mice were euthanized
for testing immune response, and the remaining mice were
challenged intratracheally with 100 ml (106 bacilli) of M.tb H37Rv
per animal. Four weeks post M.tb challenge, these mice were
sacrificed for bacterial burdens and histological assessment [48].
The whole schedule of vaccination in mice was displayed in
Figure 6.
Cytokines, T-bet and Gata-3 detection
The spleen cells from immunized mice were cultured on plates
at 2.56105 per well, and then incubated with the Esat-6/3e
peptides (10 mg/ml) for 72 h. The levels of IFN-c, IL-12, IL-4 and
Nano-Chitosan-Based Vaccine Encoding Esat-6
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e61135
IL-10 in the supernatants were determined by ELISA (Biolegend,
USA). In addition, total RNA from the spleen cells was extracted,
and the cDNA was subjected to PCR with specific primers for
mouse T-bet (up: GGAGCGGACCAACAGCATC, down:
CCACGGTGAAGGACAGGAAT), and Gata-3 (up:
TCTGGAGGAGGAACGCTAATGG, down: GAACTCTTCG-
CACACTTGGAGACTC). The ratios for T-bet/b-actin and
Gata-3/b-actin mRNA were also calculated for each sample.
Meanwhile, the expression of T-bet and Gata-3 from the spleen
cells were detected using Western blot.
Splenocyte proliferation and IFN-c+ T cell measurement
The spleen cells isolated from the mice were cultured and
incubated with the Esat-6/3e peptides or medium alone [50]. The
proliferation response of splenocytes were determined by 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
[51]. Besides, ELISPOT experiment was performed with the
assay kit (DAKEWEI, China). And the splenocytes (56105 cells/
well) were plated and treated as treated as above mentioned.
Thereafter, the biotinylated anti-IFN-c mAb was added for 2 h,
and the plate was supplemented with streptavidin-alkaline
phosphates, and the color was shown by AP-colorimetric substrate.
CTL assay in vivo
CTL assay in vivo was performed as described procedure [52].
Briefly, CTL target cells were prepared from the spleen of naı¨ve
mice and pulsed with the mixture of the Esat-6/3e peptides
(10 mg/ml) or no peptides overnight at 4uC. Peptides-pulsed
splenocytes were then labeled with a high concentration of CFSE
(5 mM) or unpulsed splenocytes with a low concentration of CFSE
(0.5 mM). 2.56106 pulsed and 2.56106 unpulsed splenocytes (1:1
ratio) were mixed and transferred to the immunized mice. The
splenocytes of mice at 18 h after treatments were isolated for
acquisition on a FACS caliber instrument (BD Biosciences, USA).
Finally, the ratio of CFSEhigh/CFSElow in the vaccinated mice was
compared.
M.tb H37Rv challenge
Fore weeks after M.tb H37Rv challenge, the left lungs and
spleen of mice were homogenized. Then, 100 ml of diluted samples
(1023, 1024, and 1025) were plated on agar plates and incubated
for 8 weeks. The number of CFU was then counted, and the data
were expressed as mean of log10 CFU value 6 standard deviation
for each group.
Besides, the lung samples of mice were subjected to hematox-
ylin-eosin (HE) staining for histological analysis. To score lung
inflammation and damage, the sections of entire lung were
observed under light microscope (LM) with software Image plus
6.0. And meanwhile, the immunohistochemistry (IHC) of the lung
sections were performed with anti-CD3 or anti-F4/80 antibody
staining, and the influx of T cells and macrophages (anti-CD3 and
anti-F4/80 positive cells) was determined.
Statistical analysis
Data were presented by mean 6 standard deviation (mean 6
SD), and analyzed using one-way ANOVA as well as multiple
comparisons between groups by student’s t test adjusted by
Bonferroni method. A probability of P#0.05 was considered
statistically significant. All analysis were conducted under SAS 9.2
(SAS Institute Inc., Cary, NC, USA).
Supporting Information
Figure S1 The particle size distributions and zeta
potential of nano-chitosan or nano-Esat-6/3e-FL plas-
mids were displayed. A. The size and ploy dispersity of nano-
Table 1. The groups of mice given with different treatments.
Esat-6/3e Esat-6 FL pIRES
nano-
chitosan BCG
Candidate group
nano-Esat-6/3e-FL + 2 + + + 2
Control group
nano-Esat-6/3e + 2 2 + + 2
nano-Esat-6-FL 2 + + + + 2
nano-Esat-6 2 + 2 + + 2
nano-FL 2 2 + + + 2
nano-chitosan 2 2 2 2 + 2
nano-pIRES 2 2 2 + + 2
Esat-6/3e-FL + 2 + + 2 2
BCG 2 2 2 2 2 +
doi:10.1371/journal.pone.0061135.t001
Figure 6. Sketch drawing of immunization procedure and challenge by M.tb H37Rv. A. C57BL/6 mice were injected intramuscularly three
times at 3-week intervals in both quadriceps muscles with different nano-plasmids, nano-chitosan, Esat-6/3e-FL or BCG. Those mice were then
boosted with Esat-6/3e peptides through intranasal administration once a week for 2 weeks, then sacrificed at 1 week after the last peptide boost. B.
Mice vaccinated with different nano-plasmids for 3 times and boosted with Esat-6/3e peptides for 2 times as above mentioned time schedules were
infected with M.tb H37Rv the airway at 1 week after the last peptide boost, and then sacrificed at 4 weeks post M.tb H37Rv challenge.
doi:10.1371/journal.pone.0061135.g006
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chitosan and nano-Esat-6/3e-FL plasmids. B. The zeta potential
of nano-chitosan and nano-Esat-6/3e-FL plasmids respectively.
(TIF)
Figure S2 The nano-Esat-6/3e-FL showed high stability
against DNase I. A. The image showed different degradation
reaction of nano-Esat-6/3e-FL and Esat-6/3e-FL with DNase I
(U) digestion (1: nano-Esat-6/3e-FL+0.1U. 2: Esat-6/3e-FL+0.1U.
3: nano-Esat-6/3e-FL+0.04U. 4: Esat-6/3e-FL+0.04U. 5: nano-
Esat-6/3e-FL+0.02U. 6: Esat-6/3e-FL+0.02U. 7: nano-Esat-6/3e-
FL. 8: Esat-6/3e-FL). B. The image displayed that ratios of
different volume mixture in nano-chitosan and Esat-6/3e-FL was
digested by same dose of DNase I (0.1U). The lane 1 and 6 were
Esat-6/3e-FL, and lane 2, 3, 4 and 5 were nano-Esat-6/3e-FL
plasmids in different volume ratio of nano-chitosan and Esat-6/3e-
FL (namely 1:1, 1:2, 1:3 and 1:4, respectively).
(TIF)
Figure S3 The detection of cytopathic effect (CPE) on
rat GMCs at 48 h and 72 h after transfection of nano-
pGCsi-GFP and liposome-pGCsi-GFP. A and D showed the
GMCs condition after transfection of liposome-2000-pGCsi-GFP.
B and E displayed the GMCs condition transfected with nano-
pGCsi-GFP. C and F showed the GMCs condition after pGCsi-
GFP transfection alone (magnification: 2006).
(TIF)
Figure S4 Cell infiltration of lung sections from the
mice challenged withM.tb was observed. The lung sections
were stained by immunohistochemistry (IHC) with anti-CD3 (A)
or anti-F4/80 (B) antibody (magnification: 2006). The percentage
of lung inflammation account for the entire lung sections of these
mice was scored by morphometric analysis (C). All experiments
were conducted three times, with the representative photos. The
data are shown as mean 6 SD (n = 6). *P,0.05, **P,0.01,
***P,0.001 versus the mice immunized with nano-chitosan or
nano-pIRES or nano-FL plasmid, and the other obvious
differences of the mice with different treatments were directly
displayed on the figures.
(TIF)
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